Publications en collaboration avec des chercheurs de Hospital Universitario Virgen del Rocío (13)

2020

  1. The role of a functional variant of TYK2 in vasculitides and infections

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 949-955

2013

  1. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylatedinterferon/ ribavirin treatment varies according to hepatitis C virus-1 subtype

    AIDS, Vol. 27, Núm. 12, pp. 1941-1947

2012

  1. Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

    PLoS ONE, Vol. 7, Núm. 11

  2. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

    Journal of Hepatology, Vol. 56, Núm. 4, pp. 788-794

2011

  1. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients

    AIDS, Vol. 25, Núm. 6, pp. 761-766

2003

  1. Diagnóstico del déficit de acil-CoA deshidrogenasa de cadena media mediante la reacción en cadena por la polimerasa en tiempo real

    Quimica Clinica, Vol. 22, Núm. 1, pp. 9-12

2001

  1. Detection of nucleotide c985 A→G mutation of medium-chain acyl-CoA dehydrogenase gene by real-time PCR

    Clinical Chemistry, Vol. 47, Núm. 5, pp. 958-959

1997

  1. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

    Journal of Hepatology, Vol. 26, Núm. 1, pp. 1-5

  2. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996 [2]

    AIDS

  3. Viraemia and p24 antigenaemia are independent risk factors for the emergence of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection

    Antiviral Therapy, Vol. 2, Núm. 2, pp. 99-104

1996

  1. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals

    Antiviral Therapy, Vol. 1, Núm. 2, pp. 105-112

  2. Efecto del tratamiento con analogos de nucleosidos en sujetos con resistencia genotipica primaria a zidovudina [1]

    Medicina Clinica

  3. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: A case-control study

    European Journal of Clinical Investigation, Vol. 26, Núm. 10, pp. 923-928